T1	Participants 381 529	recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease has progressed after platinum-containing therapy
T2	Participants 623 635	124 patients
T3	Participants 967 1088	A total of 121 patients were treated (61 afatinib, 60 cetuximab) and 68 crossed over to stage II (32 and 36 respectively)
T4	Participants 1626 1682	Patients with DRAEs leading to treatment discontinuation
T5	Participants 1967 1987	patients on afatinib
T6	Participants 2121 2145	patients after crossover
